40-60 word standalone answer.
A German biotech firm announced a clinical trial for "Molekularkleber," a molecular therapy targeting cancer cell adhesion, according to a June 2026 press release.
Mechanisms of Targeted Adhesion Disruption
Development and Mechanism of Molekularkleber
BioNano Therapeutics, a Munich-based biotechnology company, disclosed in a June 13, 2026, press statement that its experimental treatment "Molekularkleber" operates by disrupting cancer cell adhesion molecules. The therapy, described as a "targeted molecular glue," aims to prevent metastasis by weakening the structural bonds that allow cancer cells to spread. A 2025 preprint study published in Nature Cancer noted that the compound selectively binds to integrin proteins, which are critical for cell-to-cell adhesion.
The company’s lead researcher, Dr. Lena Hofmann, stated, “Our findings suggest that Molekularkleber could offer a novel approach to inhibiting tumor progression by addressing the mechanical properties of cancer cells.” However, the study emphasized that the therapy remains in preclinical stages, with human trials pending regulatory approval.
Phase I Trial Efficacy and EMA Oversight
Clinical Trial Results and Regulatory Status
As of June 2026, BioNano Therapeutics has initiated Phase I trials for Molekularkleber, according to the European Medicines Agency (EMA) database. The trial, involving 45 patients with advanced metastatic breast cancer, is evaluating the therapy’s safety and dosage. Early data, released on June 10, 2026, indicated that 30% of participants experienced stable disease, while 15% showed reduced tumor markers.
Dr. Markus Ritter, an oncologist at Charité Hospital in Berlin, noted, “The results are preliminary but suggest that targeting adhesion mechanisms could complement existing therapies. However, larger trials are needed to validate efficacy.” The EMA has designated Molekularkleber as a "priority medicinal product," expediting its review process.
Orphan Drug Designation and Competitive Market Outlook
Regulatory and Market Implications
The German Federal Institute for Drugs and Medical Devices (BfArM) has granted Molekularkleber orphan drug status for metastatic breast cancer, a classification that provides financial incentives for development. This designation, announced on May 28, 2026, reflects the therapy’s potential to address a rare but aggressive cancer subtype.
Analysts at Bernstein Research highlighted the drug’s market potential, estimating that metastatic breast cancer treatments could reach $12 billion annually by 2030. However, the firm cautioned that competitors like Merck’s Keytruda and Bristol Myers Squibb’s Opdivo already dominate the immunotherapy space. “Molekularkleber’s success hinges on demonstrating a clear therapeutic advantage,” wrote analyst Emma Lin in a June 2026 report.
Scientific Scrutiny and Future Development Milestones
Future Prospects and Scientific Debate
While BioNano Therapeutics has not disclosed a timeline for Phase II trials, the company’s CEO, Dr. Hans Engel, stated in a June 12, 2026, interview that “Molekularkleber represents a paradigm shift in cancer treatment.” The therapy’s mechanism has drawn scrutiny from the scientific community, with some experts questioning its specificity.
A June 2026 commentary in The Lancet Oncology noted, “Targeting adhesion molecules risks off-target effects, as these proteins are also vital for healthy tissue function. Rigorous testing is essential to ensure safety.” The authors called for transparency in trial design and long-term follow-up data.
What Comes Next
BioNano Therapeutics plans to present updated trial data at the 2026 American Society of Clinical Oncology (ASCO) meeting in June. The EMA’s conditional approval process could begin by late 2027, depending on trial outcomes. Meanwhile, the company is exploring partnerships with U.S.-based pharmaceutical firms to expand its research.
For now, Molekularkleber remains a promising but unproven therapy. As Dr. Hofmann acknowledged, “We are still in the early stages, but the science is compelling.” Patients and researchers alike await further results to determine whether the molecular glue will live up to its name.
Find more reporting in our Tech section.
